跳至主要内容
临床试验/NCT02333708
NCT02333708Unknown不适用

Study of Circulating Microparticles in Giant Cell Arteritis

University Hospital, Caen1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2015年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
75
试验地点
1
主要终点
Level of microparticles in the blood of patients with histologically proven giant cell arteritis.

研究概览

简要总结

To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex and with or without inflammatory syndrome.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women ≥ 18 years of age Patient affiliated to social security regimen
  • Informed and having signed the consent form to take part in the study.
  • Diagnosis of GCA, meeting at least 3 of the following 5 American College of Rheumatology (ACR) criteria for the diagnosis of GCA, including inflammatory syndrome and having
  • Either temporal artery biopsy showing characteristic GCA abnormality
  • Or inflammatory arteritis on imaging examination

排除标准

  • Persons under protection of the court or guardianship
  • Inability to understand or to follow study procedures
  • cancer diagnosed within the previous 5 years (except for non-melanoma skin cancer or in situ carcinoma of the cervix)non-contributory or inconclusive temporal artery biopsy
  • Any conditions that might interfere with MPs level: diabetes, recent endo-arterial gesture, current treatment with corticosteroids.
  • Participation in another ongoing clinical trial Current anticoagulant therapy
  • Active infectious disease

结局指标

主要结局

Level of microparticles in the blood of patients with histologically proven giant cell arteritis.

时间窗: Baseline

Level of microparticles (MPs) in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex and with or without inflammatory syndrome.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验